Outcome after primary percutaneous intervention in acute myocardial infarction: Role of microcirculatory perfusion - A crucial piece in the puzzle

European Heart Journal

Volumn 30, Issue 5, 2009, Pages 530-531

  Senior, Roxy ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CONTRAST ENHANCEMENT; EDITORIAL; ELECTROCARDIOGRAPHY; ELECTRON MICROSCOPY; HUMAN; INCIDENCE; MICROCIRCULATION; MICROEMBOLISM; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION; VASOSPASM; CORONARY ARTERY BLOOD FLOW; HEART INFARCTION; HEART VENTRICLE REMODELING; NOTE; PATHOPHYSIOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY CIRCULATION; HUMANS; MICROCIRCULATION; MYOCARDIAL INFARCTION; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 63349086778     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp043     Document Type: Editorial

References (16)

1. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, Frederick PD, Every N. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36: 2056-2063.
2. Hellermann JP, Reeder GS, Jacobsen SJ, Weston SA, Killian JM, Roger VL. Longitudinal trends in the severity of acute myocardial infarction: a population study in Olmsted County. Minnesota. Am J Epidemiol. 2002;156:246- 253.
3. Goldberg RJ, Spencer FA, Yarzebski J, Lessard D, Gore JM, Alpert JS, Dalen JE. A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). Am J Cardiol 2004;94:1373-1378.
4. Iwakura K, lto H, Kawano S, Shintani Y, Yamamoto K, Kato A, lkushima M, Tanaka K, Kitakaze M, Hori M, Higashino Y, Fujii K. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001;38:472- 477.
5. Kloner RA, Rude RE, Carlson N. Maroko PR, DeBoer LW, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first: Circulation 1980;62:945-952.
6. lto H, Maruyama A, Iwakura K. Takiuchi S. Masuyama T, Hori M, Higashino Y, Fujii K, Minamino Ti. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodelling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-228.
7. Greaves K, Dixon SR, Fejka M, O'Neill WW, Redwood SR, Marber MS, Senior R. Myocardial contrast echocardiography is superior to other known modalities for assessing myocardial reperfusion after acute myocardial infarction. Heart 2003;89: 139-144.
8. Galiuto L Garramone B, Scarà A. Rebuzzi AG, Crea F. La Torre G, Funaro S, Madonna MP, Fedele F, Agati L The extent of microvascular damage at mycardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodelling. Results of the multicenter study 'Acute Myocardial Infarction Contrast Imaging' (A.M.I.C.I.). J Am Coll Cardiol 2008;51:552-559.
9. Funaro S, La Torre G, Madonna M, Galiuto L Scará A, Labbadia A, Canali E, Mattatelli A, Fedele F, Alessandrini F, Crea F. Agati L on behalf of the AMICI Investigators. Incidence, determinants and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention. Results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009;30:566-575. First published on 18 December 2008. doi: 10.1093/eurheartj/ehn529.
10. Bolognese L Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, Antoniucci D. Impact of microvascular dysfunction on left ventricular remodelling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004;109:1121-1126.
11. Jeetley P, Swinburn J, Hickman M, Bellenger N, Penneil D, Senior R. Myocardial contrast echocardiography predicts left ventricular remodelling following acute myocardial infarction. J Am Soc Echocardiogr 2004;17:1030-1036.
12. Sutton MJ, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald E for the SAVE investigators. Cardiovascular death and left ventricular remodelling two years after myocardial infarction: baseline predictors and impact of long-term use of Captopril: information from the survival and ventricular enlargement (SAVE) trial. Circulation 1997;96: 3294-3299.
13. Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A. Carvedilol prevents remodelling in patients with left ventricular dysfunction following acute myocardial infarction. Am Heart J 1999;137:646-652.
14. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, Rebuzzi AG, Crea F. Temporal evolution and functional outcome of no-reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 2003;89:731 -737.
15. Senior R, Villanueva F, Vannan MA. Myocardial contrast chocardiography in acute coronary syndromes. Cardiol Clin 2004;22:253-267.
16. Tcheng JE, Kandzari DE, Grines CL, Cox DA. Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003;108:1316-1323.